TY - JOUR
T1 - Predictors of response to corticosteroids for dyspnea in advanced cancer patients
T2 - a preliminary multicenter prospective observational study
AU - Mori, Masanori
AU - Shirado, Akemi Naito
AU - Morita, Tatsuya
AU - Okamoto, Kenichiro
AU - Matsuda, Yoshinobu
AU - Matsumoto, Yoshihisa
AU - Yamada, Hirohide
AU - Sakurai, Hiroki
AU - Aruga, Etsuko
AU - Kaneishi, Keisuke
AU - Watanabe, Hiroaki
AU - Yamaguchi, Takashi
AU - Odagiri, Takuya
AU - Hiramoto, Shuji
AU - Kohara, Hiroyuki
AU - Matsuo, Naoki
AU - Katayama, Hideki
AU - Nishi, Tomohiro
AU - Matsui, Takashi
AU - Iwase, Satoru
N1 - Funding Information:
This research in (partially) supported by the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development, AMED (15ck0106059h0002).
Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Purpose: Although corticosteroids can relieve dyspnea in advanced cancer patients, factors predicting the response remain unknown. We aimed to explore potential factors predicting the response to corticosteroids for dyspnea in advanced cancer patients. Methods: In this preliminary multicenter prospective observational study, we included patients who had metastatic or locally advanced cancer, were receiving specialized palliative care services, and had a dyspnea intensity of ≥3 on a 0–10 Numerical Rating Scale (NRS) (worst during the last 24 h). The primary endpoint was NRS of dyspnea on day 3 after the administration of corticosteroids. Univariate/multivariate analyses were conducted to identify factors predicting ≥1-point reduction in NRS. Results: Of 74 patients who received corticosteroids, 50 (68%) showed ≥1-point reduction in dyspnea NRS. Factors that significantly predicted the response were an age of 70 years or older (82 vs. 53%, p = 0.008), absence of liver metastases (77 vs. 46%, p = 0.001), Palliative Prognostic Index (PPI) ≤ 6 (90 vs. 61%, p = 0.041), presence of pleuritis carcinomatosa with a small collection of pleural effusions (84 vs. 55%, p = 0.011), presence of audible wheezes (94 vs. 60%, p = 0.014), and baseline dyspnea NRS ≥7 (76% vs. 52%, p = 0.041). In a multivariate analysis, factors predicting response included PPI <6 (odds ratio (OR), 36.2; p = 0.021), baseline dyspnea NRS (worst) ≥7 (OR, 6.6; p = 0.036), and absence of liver metastases (OR, 0.19; p = 0.029) or ascites/liver enlargement (OR, 0.13; p = 0.050). Conclusions: The patient characteristics, etiologies of dyspnea, and clinical manifestations may predict responses to corticosteroids for dyspnea. Larger prospective studies are promising to confirm our findings.
AB - Purpose: Although corticosteroids can relieve dyspnea in advanced cancer patients, factors predicting the response remain unknown. We aimed to explore potential factors predicting the response to corticosteroids for dyspnea in advanced cancer patients. Methods: In this preliminary multicenter prospective observational study, we included patients who had metastatic or locally advanced cancer, were receiving specialized palliative care services, and had a dyspnea intensity of ≥3 on a 0–10 Numerical Rating Scale (NRS) (worst during the last 24 h). The primary endpoint was NRS of dyspnea on day 3 after the administration of corticosteroids. Univariate/multivariate analyses were conducted to identify factors predicting ≥1-point reduction in NRS. Results: Of 74 patients who received corticosteroids, 50 (68%) showed ≥1-point reduction in dyspnea NRS. Factors that significantly predicted the response were an age of 70 years or older (82 vs. 53%, p = 0.008), absence of liver metastases (77 vs. 46%, p = 0.001), Palliative Prognostic Index (PPI) ≤ 6 (90 vs. 61%, p = 0.041), presence of pleuritis carcinomatosa with a small collection of pleural effusions (84 vs. 55%, p = 0.011), presence of audible wheezes (94 vs. 60%, p = 0.014), and baseline dyspnea NRS ≥7 (76% vs. 52%, p = 0.041). In a multivariate analysis, factors predicting response included PPI <6 (odds ratio (OR), 36.2; p = 0.021), baseline dyspnea NRS (worst) ≥7 (OR, 6.6; p = 0.036), and absence of liver metastases (OR, 0.19; p = 0.029) or ascites/liver enlargement (OR, 0.13; p = 0.050). Conclusions: The patient characteristics, etiologies of dyspnea, and clinical manifestations may predict responses to corticosteroids for dyspnea. Larger prospective studies are promising to confirm our findings.
KW - Cancer
KW - Corticosteroids
KW - Dyspnea
KW - Palliative care
KW - Predictors
UR - http://www.scopus.com/inward/record.url?scp=85000351031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85000351031&partnerID=8YFLogxK
U2 - 10.1007/s00520-016-3507-5
DO - 10.1007/s00520-016-3507-5
M3 - Article
C2 - 27900548
AN - SCOPUS:85000351031
SN - 0941-4355
VL - 25
SP - 1169
EP - 1181
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 4
ER -